IL31R_HUMAN » Interleukin-31 receptor subunit alpha

IL31R_HUMAN » Interleukin-31 receptor subunit alpha
Magnify IL31R_HUMAN » Interleukin-31 receptor subunit alphaEnlarged view of image
3D view in GLMol or JMol

gray dot

Download Coordinates

gray dot

Topology in Plasma membrane
Topologyextracellular side
cytoplasmic side
IL31R_HUMAN » Interleukin-31 receptor subunit alpha » IL-31 receptor subunit alpha; IL-31R subunit alpha; IL-31R-alpha; IL-31RA; Cytokine receptor-like 3;GLM-R;hGLM-R; Gp130-like monocyte receptor;Gp130-like receptor; ZcytoR17;
Hydrophobic Thickness 36.0 ± 1.8 Å
Tilt Angle 9 ± 6°
ΔGtransfer -42.1 kcal/mol
ΔGfold -19.9 kcal/mol
Links UniProtKB, Pfam, Interpro, iHOP, STRING, HGNC
Topology Out
TM Segments 517-543 (515-545)
Pathways none
PDB none
OPM none
Complexes none
Interactions

IL6RB, Complex: IL31R:IL6RB, PubMed

LIFR, Complex: LIFR:IL31R, PubMed

Domains

AA: 27-119, PDBID: 1BQU, Subunit B, Seq Identity:30%, Interleukin-6 receptor alpha chain, binding

AA: 123-215, PDBID: 1QR4, Subunit B, Seq Identity:26%, Fibronectin type III domain

AA: 425-507, PDBID: 3L5H, Subunit A, Seq Identity:37%, Fibronectin type III domain

UniProt annotation for IL31R_HUMAN » Interleukin-31 receptor subunit alpha
FUNCTION: Associates with OSMR to form the interleukin-31 receptor which activates STAT3 and to a lower extent STAT1 and STAT5. May function in skin immunity.

SUBUNIT: Heterodimer with OSMR. Interacts with JAK1 and STAT3.

TISSUE SPECIFICITY: Expressed at low levels in testis, ovary, brain, prostate, placenta, thymus, bone marrow, trachea and skin. Detected in all of the myelomonocytic lineage. Expressed in CD14- and CD56-positive blood cells and by macrophages (at protein level).

INDUCTION: Up-regulated in lesional keratinocytes of patients with atopic dermatitis. Up-regulated by IFNG/IFN-gamma and bacterial lipopolysaccharides (LPS).

DISEASE: Amyloidosis, primary localized cutaneous, 2 (PLCA2) OMIM: A primary amyloidosis characterized by localized cutaneous amyloid deposition. This condition usually presents with itching (especially on the lower legs) and visible changes of skin hyperpigmentation and thickening that may be exacerbated by chronic scratching and rubbing. Primary localized cutaneous amyloidosis is often divided into macular and lichen subtypes although many affected individuals often show both variants coexisting. Lichen amyloidosis characteristically presents as a pruritic eruption of grouped hyperkeratotic papules with a predilection for the shins, calves, ankles and dorsa of feet and thighs. Papules may coalesce to form hyperkeratotic plaques that can resemble lichen planus, lichen simplex or nodular prurigo. Macular amyloidosis is characterized by small pigmented macules that may merge to produce macular hyperpigmentation, sometimes with a reticulate or rippled pattern. In macular and lichen amyloidosis, amyloid is deposited in the papillary dermis in association with grouped colloid bodies, thought to represent degenerate basal keratinocytes. The amyloid deposits probably reflect a combination of degenerate keratin filaments, serum amyloid P component, and deposition of immunoglobulins. mutations affecting the gene represented in this entry.

UniProt features for IL31R_HUMAN » Interleukin-31 receptor subunit alpha
SIGNAL 1 19
CHAIN 20 732 Interleukin-31 receptor subunit alpha.
DOMAIN 22 116 Fibronectin type-III 1.
DOMAIN 121 222 Fibronectin type-III 2.
DOMAIN 223 315 Fibronectin type-III 3.
DOMAIN 319 416 Fibronectin type-III 4.
DOMAIN 421 512 Fibronectin type-III 5.
Amino Acid Sequence for IL31R_HUMAN » Interleukin-31 receptor subunit alpha
MMWTWALWML PSLCKFSLAA LPAKPENISC VYYYRKNLTC TWSPGKETSY TQYTVKRTYA FGEKHDNCTT NSSTSENRAS CSFFLPRITI PDNYTIEVEA ENGDGVIKSH MTYWRLENIA KTEPPKIFRV KPVLGIKRMI QIEWIKPELA PVSSDLKYTL RFRTVNSTSW MEVNFAKNRK DKNQTYNLTG LQPFTEYVIA LRCAVKESKF WSDWSQEKMG MTEEEAPCGL ELWRVLKPAE ADGRRPVRLL WKKARGAPVL EKTLGYNIWY YPESNTNLTE TMNTTNQQLE LHLGGESFWV SMISYNSLGK SPVATLRIPA IQEKSFQCIE VMQACVAEDQ LVVKWQSSAL DVNTWMIEWF PDVDSEPTTL SWESVSQATN WTIQQDKLKP FWCYNISVYP MLHDKVGEPY SIQAYAKEGV PSEGPETKVE NIGVKTVTIT WKEIPKSERK GIICNYTIFY QAEGGKGFSK TVNSSILQYG LESLKRKTSY IVQVMASTSA GGTNGTSINF KTLSFSVFEI ILITSLIGGG LLILIILTVA YGLKKPNKLT HLCWPTVPNP AESSIATWHG DDFKDKLNLK ESDDSVNTED RILKPCSTPS DKLVIDKLVV NFGNVLQEIF TDEARTGQEN NLGGEKNGYV TCPFRPDCPL GKSFEELPVS PEIPPRKSQY LRSRMPEGTR PEAKEQLLFS GQSLVPDHLC EEGAPNPYLK NSVTAREFLV SEKLPEHTKG EV